首页> 外文期刊>Journal of population therapeutics and clinical pharmacology >Comparison of the Adherence and Persistence to Inhaled Corticosteroids Among Adult Patients with Public and Private Drug Insurance Plans
【24h】

Comparison of the Adherence and Persistence to Inhaled Corticosteroids Among Adult Patients with Public and Private Drug Insurance Plans

机译:具有公共和私人药物保险计划的成年患者对吸入性糖皮质激素的依从性和持久性的比较

获取原文
           

摘要

Background Despite important differences in reimbursement procedures between private and public drug insurance plans in Quebec (Canada), no study has evaluated the impact of the type of drug insurance on the use of essential medications such as inhaled corticosteroids (ICS). The lack of data might be attributable, at least in part, to the absence of a provincial medication database for patients with private drug insurance. Objectives To compare patient's adherence and persistence to ICS between Quebec residents (Canada) with private and public drug insurance. Methods A matched cohort design with patients selected from the database of the Régie de l'assurance maladie du Québec (RAMQ) and from reMed, a database that we have put in place for Quebec residents covered by a private drug insurance, was used. ICS users with private drug insurance were selected from reMed between 2008 and 2010 and matched to ICS users with public drug insurance selected from the RAMQ database. Patient's adherence, measured with the proportion of prescribed days covered (PPDC) and persistence over one year, was compared between patients privately and publicly insured using linear regression and Cox regression models. Results This study included 330 and 1,109 ICS users with private and public drug insurance, respectively. Patients privately insured were significantly less adherent than patients publicly insured (adjusted mean difference of PPDC: -9.7%; 95% CI: -13.2% to -6.5%). Moreover, patients privately insured were found to be 52% more likely to stop ICS during the first year than patients publicly insured (adjusted HR=1.5; 95% CI: 1.2 to 2.0). Conclusions Although adherence and persistence were rather low in both groups, patients with public drug insurance appeared to have greater adherence and persistence to ICS than patients with private drug insurance. Differences in reimbursement policies might explain the observed differences.
机译:背景尽管尽管魁北克(加拿大)的私人和公共药物保险计划的报销程序存在重大差异,但尚无研究评估药物保险类型对使用基本药物(例如吸入性糖皮质激素(ICS))的影响。数据的缺乏可能至少部分归因于缺乏针对私人药物保险患者的省级药物数据库。目的比较私人和公共药物保险对魁北克居民(加拿大)患者对ICS的依从性和持久性。方法采用与队列匹配的设计,患者选自魁北克省医疗保障数据库(RAMQ)和reMed(我们已为魁北克居民建立的拥有私人毒品保险的数据库)。从2008年至2010年间从reMed中选择了拥有私人毒品保险的ICS用户,并与从RAMQ数据库中选择具有公共毒品保险的ICS用户进行了匹配。使用线性回归和Cox回归模型比较了私人和公共保险患者的患者依从性(以规定的保险天数(PPDC)和一年的持续时间来衡量)。结果这项研究分别包括330和1109位ICS用户,分别拥有私人和公共药物保险。私人保险患者的依从性明显低于公共保险患者(PPDC的调整后平均差异:-9.7%; 95%CI:-13.2%至-6.5%)。此外,发现私人保险的患者在第一年停药的可能性比公开保险的患者高52%(调整后的HR = 1.5; 95%CI:1.2至2.0)。结论尽管两组的依从性和持久性均较低,但公共药物保险患者对ICS的依从性和持久性似乎比私人药物保险患者更高。报销政策的差异可能解释了观察到的差异。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号